The role of ranibizumab in the management of diabetic retinopathy

Salman Sarwar, Mostafa Hanout, Mohammad Ali Sadiq, Mohamed K. Soliman, Aniruddha Agarwal, Diana V. Do, Quan Dong Nguyen

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

Diabetic retinopathy (DR) comprises a major challenge to the public health and economy, being the leading cause of vision loss in working-aged adults in developed countries. If left untreated, DR will eventually progress leading to devastating blinding consequences including diabetic macular edema (DME), vitreous hemorrhage and tractional retinal detachment. Ranibizumab is a humanized monoclonal antibody fragment that targets the vascular endothelial growth factor (VEGF). It has been approved by the US FDA for the treatment of DME and DR in patients with DME. Given its proven efficacy and favorable safety profile, it has been widely used as one of the preferred therapeutic option for DME in modern clinical practice. This review provides a comprehensive overview on the safety and efficacy of ranibizumab in the management of DR and its associated sight-threatening microvascular complications.

Original languageEnglish (US)
Pages (from-to)329-340
Number of pages12
JournalExpert Review of Ophthalmology
Volume10
Issue number4
DOIs
StatePublished - Aug 1 2015

Fingerprint

Macular Edema
Diabetic Retinopathy
Monoclonal antibodies
Public health
Safety
Vitreous Hemorrhage
Immunoglobulin Fragments
Retinal Detachment
Developed Countries
Vascular Endothelial Growth Factor A
Public Health
Ranibizumab
Therapeutics
Intercellular Signaling Peptides and Proteins

Keywords

  • Ranibizumab
  • intravitreal injection
  • laser photocoagulation
  • macular edema
  • monoclonal antibodies. neovascularization
  • retinopathy severity
  • vascular endothelial growth factor
  • vitreous hemorrhage

ASJC Scopus subject areas

  • Biomedical Engineering
  • Ophthalmology
  • Optometry

Cite this

Sarwar, S., Hanout, M., Sadiq, M. A., Soliman, M. K., Agarwal, A., Do, D. V., & Nguyen, Q. D. (2015). The role of ranibizumab in the management of diabetic retinopathy. Expert Review of Ophthalmology, 10(4), 329-340. https://doi.org/10.1586/17469899.2015.1057506

The role of ranibizumab in the management of diabetic retinopathy. / Sarwar, Salman; Hanout, Mostafa; Sadiq, Mohammad Ali; Soliman, Mohamed K.; Agarwal, Aniruddha; Do, Diana V.; Nguyen, Quan Dong.

In: Expert Review of Ophthalmology, Vol. 10, No. 4, 01.08.2015, p. 329-340.

Research output: Contribution to journalReview article

Sarwar, S, Hanout, M, Sadiq, MA, Soliman, MK, Agarwal, A, Do, DV & Nguyen, QD 2015, 'The role of ranibizumab in the management of diabetic retinopathy', Expert Review of Ophthalmology, vol. 10, no. 4, pp. 329-340. https://doi.org/10.1586/17469899.2015.1057506
Sarwar S, Hanout M, Sadiq MA, Soliman MK, Agarwal A, Do DV et al. The role of ranibizumab in the management of diabetic retinopathy. Expert Review of Ophthalmology. 2015 Aug 1;10(4):329-340. https://doi.org/10.1586/17469899.2015.1057506
Sarwar, Salman ; Hanout, Mostafa ; Sadiq, Mohammad Ali ; Soliman, Mohamed K. ; Agarwal, Aniruddha ; Do, Diana V. ; Nguyen, Quan Dong. / The role of ranibizumab in the management of diabetic retinopathy. In: Expert Review of Ophthalmology. 2015 ; Vol. 10, No. 4. pp. 329-340.
@article{fe33d9e6b7784581b81f5f625eb10a66,
title = "The role of ranibizumab in the management of diabetic retinopathy",
abstract = "Diabetic retinopathy (DR) comprises a major challenge to the public health and economy, being the leading cause of vision loss in working-aged adults in developed countries. If left untreated, DR will eventually progress leading to devastating blinding consequences including diabetic macular edema (DME), vitreous hemorrhage and tractional retinal detachment. Ranibizumab is a humanized monoclonal antibody fragment that targets the vascular endothelial growth factor (VEGF). It has been approved by the US FDA for the treatment of DME and DR in patients with DME. Given its proven efficacy and favorable safety profile, it has been widely used as one of the preferred therapeutic option for DME in modern clinical practice. This review provides a comprehensive overview on the safety and efficacy of ranibizumab in the management of DR and its associated sight-threatening microvascular complications.",
keywords = "Ranibizumab, intravitreal injection, laser photocoagulation, macular edema, monoclonal antibodies. neovascularization, retinopathy severity, vascular endothelial growth factor, vitreous hemorrhage",
author = "Salman Sarwar and Mostafa Hanout and Sadiq, {Mohammad Ali} and Soliman, {Mohamed K.} and Aniruddha Agarwal and Do, {Diana V.} and Nguyen, {Quan Dong}",
year = "2015",
month = "8",
day = "1",
doi = "10.1586/17469899.2015.1057506",
language = "English (US)",
volume = "10",
pages = "329--340",
journal = "Expert Review of Ophthalmology",
issn = "1746-9899",
number = "4",

}

TY - JOUR

T1 - The role of ranibizumab in the management of diabetic retinopathy

AU - Sarwar, Salman

AU - Hanout, Mostafa

AU - Sadiq, Mohammad Ali

AU - Soliman, Mohamed K.

AU - Agarwal, Aniruddha

AU - Do, Diana V.

AU - Nguyen, Quan Dong

PY - 2015/8/1

Y1 - 2015/8/1

N2 - Diabetic retinopathy (DR) comprises a major challenge to the public health and economy, being the leading cause of vision loss in working-aged adults in developed countries. If left untreated, DR will eventually progress leading to devastating blinding consequences including diabetic macular edema (DME), vitreous hemorrhage and tractional retinal detachment. Ranibizumab is a humanized monoclonal antibody fragment that targets the vascular endothelial growth factor (VEGF). It has been approved by the US FDA for the treatment of DME and DR in patients with DME. Given its proven efficacy and favorable safety profile, it has been widely used as one of the preferred therapeutic option for DME in modern clinical practice. This review provides a comprehensive overview on the safety and efficacy of ranibizumab in the management of DR and its associated sight-threatening microvascular complications.

AB - Diabetic retinopathy (DR) comprises a major challenge to the public health and economy, being the leading cause of vision loss in working-aged adults in developed countries. If left untreated, DR will eventually progress leading to devastating blinding consequences including diabetic macular edema (DME), vitreous hemorrhage and tractional retinal detachment. Ranibizumab is a humanized monoclonal antibody fragment that targets the vascular endothelial growth factor (VEGF). It has been approved by the US FDA for the treatment of DME and DR in patients with DME. Given its proven efficacy and favorable safety profile, it has been widely used as one of the preferred therapeutic option for DME in modern clinical practice. This review provides a comprehensive overview on the safety and efficacy of ranibizumab in the management of DR and its associated sight-threatening microvascular complications.

KW - Ranibizumab

KW - intravitreal injection

KW - laser photocoagulation

KW - macular edema

KW - monoclonal antibodies. neovascularization

KW - retinopathy severity

KW - vascular endothelial growth factor

KW - vitreous hemorrhage

UR - http://www.scopus.com/inward/record.url?scp=84937540819&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84937540819&partnerID=8YFLogxK

U2 - 10.1586/17469899.2015.1057506

DO - 10.1586/17469899.2015.1057506

M3 - Review article

AN - SCOPUS:84937540819

VL - 10

SP - 329

EP - 340

JO - Expert Review of Ophthalmology

JF - Expert Review of Ophthalmology

SN - 1746-9899

IS - 4

ER -